COMPANY

Atsena Therapeutics, Inc.

1 open job · last seen Oct 23, 2026 · 5 sources

Profile checked Oct 10, 2026

Keywords: Leber Congenital Amaurosis X-linked Retinoschisis LCA1 ATSN-201 ATSN-101

1Open jobs $150.0MRaised (2 yrs)2Trials (company is sponsor)2NIH grants

Hiring

Title	Location (from posting)	Employer posted	First seen
Associate Director or Director, Regulatory Strategy (Clinical & Nonclinical)	Durham, North Carolina, United States	Not stated	Oct 11, 2026

See all 1 job

Funding and NIH signals

NIH award NIH awarded $731K (SBIR Phase II 5R44EY037156-02, continuation, notice Sep 1, 2026); 1 role open. NIH RePORTER 5R44EY037156-02 (Sep 1, 2026)
Evidence (1 event)
- Sep 1, 2026 · NIH RePORTER 5R44EY037156-02
  Organization: ATSENA THERAPEUTICS, INC.; City/State: DURHAM, NC; Project number: 5R44EY037156-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-01; FY total cost (award amount): 731026; Administering IC: National Eye Institute; Project title: Manufacturing Development and Commercial Readiness of an Adeno-Associated Virus-Based Gene Therapy for the Treatment of Leber Congenital Amaurosis Type 1; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Raises and deals from press releases

Raise Series C · $150M · announced Apr 2, 2025 Company release ↗
Source quote
- Apr 2, 2025 · Company release ↗
  “Atsena Therapeutics Announces Oversubscribed $150 Million Series C Financing to Further Advance Ocular Gene Therapy Programs”

Raises announced in these releases: $150M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Apr 2, 2025 Raise Private equity round — Series C: $150M (total, as published), announced Apr 2, 2025. Source: company release on GlobeNewswire. source ↗
Apr 2, 2025 Raise Series C · $150M source ↗
Aug 22, 2023 Trial start Phase 3: ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis source ↗
Oct 22, 2019 Trial start Phase 1/Phase 2: Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D source ↗

Upcoming milestones

2028-04 (ESTIMATED) · Phase 3 · ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis · NCT05878860

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $150.0M. Last 2 years.

Apr 2, 2025 Private equity round — Series C: $150M (total, as published), announced Apr 2, 2025. Source: company release on GlobeNewswire. source ↗

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT05878860	ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis	Phase 3	Recruiting	Aug 22, 2023	2028-04 (estimated)
NCT03920007	Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D	Phase 1/Phase 2	Active, not recruiting	Oct 22, 2019	May 19, 2023 (actual)

NIH awards 2

Annual award amounts. Total $1.6M.

Sep 1, 2026 NIH award 5R44EY037156-02 FY2026: $731,026 awarded for that fiscal year; activity R44 (SBIR); PI MOUILLESSEAUX, KEVIN P; recipient as written: ATSENA THERAPEUTICS, INC., DURHAM, NC. Manufacturing Development and Comm source ↗
Sep 11, 2025 NIH award 1R44EY037156-01 FY2025: $870,675 awarded for that fiscal year; activity R44 (SBIR); PI MOUILLESSEAUX, KEVIN P; recipient as written: ATSENA THERAPEUTICS, INC., DURHAM, NC. Manufacturing Development and Comm source ↗

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

InvestorListed in the portfolio of Bain Capital Life Sciences (captured Oct 12, 2026). portfolio page ↗

Open jobs 1

Title	Location (from posting, not HQ)	Employer posted	First seen	Level
Associate Director or Director, Regulatory Strategy (Clinical & Nonclinical)	Durham, North Carolina, United States	Not stated	Oct 11, 2026	Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Connect

See your connections at Atsena Therapeutics on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18